Haiyun Wang1, Shijia Zhang1,2, Douglas Yee1, Saonli Basu3, Heather Beckwith1, David Potter1, Anne Blaes4. 1. Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, 420 Delaware St SE, MMC 480, Minneapolis, MN, 55455, USA. 2. Illinois CancerCare, 8940 N Wood Sage Rd, Peoria, IL, 61615, USA. 3. Division of Biostatistics, School of Public Health, University of Minnesota, 420 Delaware St SE, Minneapolis, MN, 55455, USA. 4. Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, 420 Delaware St SE, MMC 480, Minneapolis, MN, 55455, USA. blaes004@umn.edu.
Abstract
PURPOSE: The impact of an increased body mass index (BMI) on outcomes of neoadjuvant chemotherapy (NACT) in breast cancer remains controversial. The purpose of this study was to analyze the impact of BMI on pathological complete response (pCR) rates for operable breast cancer after NACT. METHODS: We searched Medline, Embase, and Web of Science database for observational studies and randomized controlled trials that reported the association of BMI with pCR after NACT. We performed a meta-analysis to assess the impact of BMI on pCR rate. RESULTS: We identified 13 studies including a total of 18,702 women with operable breast cancer who underwent NACT. Two studies were pooled analyses of prospective clinical trials (10,669 patients); the rest were case-control studies (8033 patients). All studies provided data of two BMI groups (BMI < 25 vs. BMI ≥ 25). Pooled analyses demonstrated that overweight/obese women were less likely to achieve pCR after NACT as compared to under-/normal weight women (odds ratio (OR) = 0.80; 95% confidence interval (CI): 0.68-0.93). Eleven studies provided data of three BMI groups (BMI < 25, 25 ≤ BMI < 30, BMI ≥ 30). Based on pooled analyses, both overweight and obese groups were less likely to achieve pCR with NACT as compared to under-/normal weight group, (OR = 0.77, 95% CI 0.65-0.93 and OR = 0.68, 95% CI 0.61-0.77, respectively). CONCLUSIONS: Overweight and obese breast cancer patients had a lower pCR rate with NACT compared to patients with under-/normal weight. Further prospective studies may help confirm this finding and investigate possible mechanisms.
PURPOSE: The impact of an increased body mass index (BMI) on outcomes of neoadjuvant chemotherapy (NACT) in breast cancer remains controversial. The purpose of this study was to analyze the impact of BMI on pathological complete response (pCR) rates for operable breast cancer after NACT. METHODS: We searched Medline, Embase, and Web of Science database for observational studies and randomized controlled trials that reported the association of BMI with pCR after NACT. We performed a meta-analysis to assess the impact of BMI on pCR rate. RESULTS: We identified 13 studies including a total of 18,702 women with operable breast cancer who underwent NACT. Two studies were pooled analyses of prospective clinical trials (10,669 patients); the rest were case-control studies (8033 patients). All studies provided data of two BMI groups (BMI < 25 vs. BMI ≥ 25). Pooled analyses demonstrated that overweight/obesewomen were less likely to achieve pCR after NACT as compared to under-/normal weight women (odds ratio (OR) = 0.80; 95% confidence interval (CI): 0.68-0.93). Eleven studies provided data of three BMI groups (BMI < 25, 25 ≤ BMI < 30, BMI ≥ 30). Based on pooled analyses, both overweight and obese groups were less likely to achieve pCR with NACT as compared to under-/normal weight group, (OR = 0.77, 95% CI 0.65-0.93 and OR = 0.68, 95% CI 0.61-0.77, respectively). CONCLUSIONS: Overweight and obese breast cancerpatients had a lower pCR rate with NACT compared to patients with under-/normal weight. Further prospective studies may help confirm this finding and investigate possible mechanisms.
Entities:
Keywords:
Breast cancer; Neoadjuvant chemotherapy; Obesity; Pathological complete response
Authors: Katherine M Flegal; Deanna Kruszon-Moran; Margaret D Carroll; Cheryl D Fryar; Cynthia L Ogden Journal: JAMA Date: 2016-06-07 Impact factor: 56.272
Authors: Shaheenah Dawood; Kristine Broglio; Ana M Gonzalez-Angulo; Shu-Wan Kau; Rabiul Islam; Gabriel N Hortobagyi; Massimo Cristofanilli Journal: Clin Cancer Res Date: 2008-03-15 Impact factor: 12.531
Authors: Laura E G Warren; Jennifer A Ligibel; Yu-Hui Chen; Linh Truong; Paul J Catalano; Jennifer R Bellon Journal: Ann Surg Oncol Date: 2016-07-22 Impact factor: 5.344
Authors: Marilyn J Borugian; Samuel B Sheps; Charmaine Kim-Sing; Ivo A Olivotto; Cheri Van Patten; Bruce P Dunn; Andrew J Coldman; John D Potter; Richard P Gallagher; T Gregory Hislop Journal: Am J Epidemiol Date: 2003-11-15 Impact factor: 4.897
Authors: Priya Rastogi; Stewart J Anderson; Harry D Bear; Charles E Geyer; Morton S Kahlenberg; André Robidoux; Richard G Margolese; James L Hoehn; Victor G Vogel; Shaker R Dakhil; Deimante Tamkus; Karen M King; Eduardo R Pajon; Mary Johanna Wright; Jean Robert; Soonmyung Paik; Eleftherios P Mamounas; Norman Wolmark Journal: J Clin Oncol Date: 2008-02-10 Impact factor: 44.544
Authors: S P Somashekhar; Richa Jaiswal; Rohit Kumar; B C Ashok; Susmita Rakshit; Amit Rauthan; Poonam Patil; Nitin Yashas; H K Karthik; Archa Prasad; Herra Islam; K R Ashwin Journal: Eur J Breast Health Date: 2022-07-01
Authors: Nina Ditsch; Achim Wöcke; Michael Untch; Christian Jackisch; Ute-Susann Albert; Maggie Banys-Paluchowski; Ingo Bauerfeind; Jens-Uwe Blohmer; Wilfried Budach; Peter Dall; Eva Maria Fallenberg; Peter A Fasching; Tanja N Fehm; Michael Friedrich; Bernd Gerber; Oleg Gluz; Nadia Harbeck; Jörg Heil; Jens Huober; Hans H Kreipe; David Krug; Thorsten Kühn; Sherko Kümmel; Cornelia Kolberg-Liedtke; Sibylle Loibl; Diana Lüftner; Michael Patrick Lux; Nicolai Maass; Christoph Mundhenke; Ulrike Nitz; Tjoung-Won Park-Simon; Toralf Reimer; Kerstin Rhiem; Achim Rody; Marcus Schmidt; Andreas Schneeweiss; Florian Schütz; Hans-Peter Sinn; Christine Solbach; Erich-Franz Solomayer; Elmar Stickeler; Christoph Thomssen; Isabell Witzel; Volkmar Müller; Wolfgang Janni; Marc Thill Journal: Breast Care (Basel) Date: 2022-05-05 Impact factor: 2.268
Authors: Lishi Lin; Marcel Soesan; Dorieke E M van Balen; Jos H Beijnen; Alwin D R Huitema Journal: Breast Cancer Res Treat Date: 2022-08-16 Impact factor: 4.624
Authors: Rebecca D Kehm; Adana A M Llanos; Jasmine A McDonald; Parisa Tehranifar; Mary Beth Terry Journal: Cancers (Basel) Date: 2022-08-26 Impact factor: 6.575